Evercore ISI Group Downgrades Legend Biotech to In-Line, Announces $20 Price Target
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsDowngradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Evercore ISI Group analyst Umer Raffat downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to In-Line and announces $20 price target.
Evercore ISI Group analyst Umer Raffat downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to In-Line and announces $20 price target.
